Related references
Note: Only part of the references are listed.Evidence vs. Access: Can Twenty-First-Century Drug Regulation Refine the Tradeoffs?
J. Woodcock
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Adaptive Licensing: Taking the Next Step in the Evolution of Drug Approval
H-G Eichler et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
European Perspective on Risk Management and Drug Safety
J. Raine et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response
Hans-Georg Eichler et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Developing the Sentinel System - A National Resource for Evidence Development
Rachel E. Behrman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project
Preciosa M. Coloma et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2011)
Getting to grips with the new European Union pharmacovigilance legislation
Patrick Waller
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2011)
European Medicines Agency review of post-authorisation studies with implications for the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance
Kevin V. Blake et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2011)
Why Drug Safety Should Not Take a Back Seat to Efficacy
Virginia Barbour et al.
PLOS MEDICINE (2011)
Regulatory Action on Rosiglitazone by the US Food and Drug Administration
Janet Woodcock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Safe Drugs and the Cost of Good Intentions
Hans-Georg Eichler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Managing Drug-Risk Information - What to Do with All Those New Numbers
Jerry Avorn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Early access to new medicines
A. Breckenridge et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Benefits and Risks of Drug Treatments How to Combine the Best Evidence on Benefits With the Best Data About Adverse Effects
Jan P. Vandenbroucke et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma
Hans-Georg Eichler et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Monitoring the safety of licensed medicines
A Breckenridge et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Detection, verification, and quantification of adverse drug reactions
BHC Stricker et al.
BRITISH MEDICAL JOURNAL (2004)
A model for the future conduct of pharmacovigilance
PC Waller et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2003)
Share Paper
